多替阿巴拉米片要怎么用呢？

It is an innovative drug for AIDS treatment by ViiV Healthcare, a joint venture company of GlaxoSmithKline (GSK). It is currently the only three-in-one compound drug containing dolutegravir (DTG). It has the characteristics of good tolerance, high resistance barrier and few drug interactions. Clinical studies have shown that dolutegravir tablets can significantly reduce the medication burden of AIDS patients, thereby increasing patients' medication compliance and significantly improving their quality of life. So how should patients take dolutegravir tablets?

This product should be taken under the guidance of a physician with experience in treating HIV infection.

Adults and adolescents (weighing at least 40 kg)

For adults and adolescents, the recommended dose is one tablet once daily.

Adults or adolescents whose body weight is less than 40 kg should not be given as this product is a fixed-dose tablet and the dose cannot be reduced.

This product is a fixed-dose tablet and should not be used in patients who require dose adjustments. If discontinuation or dose adjustment of one of the active ingredients is necessary, separate formulations of dolutegravir, abacavir, or lamivudine may be used. In these cases, physicians should refer to the respective product information for these drugs.

Miss a dose

If the patient misses a dose of this product and there are more than 4 hours before the next dose, the patient should take this product as soon as possible. If the next dose is less than 4 hours away, patients should not take the missed dose and simply resume their usual dosing schedule.

elderly patients

There are limited data on the use of dolutegravir, abacavir, and lamivudine in patients 65 years and older. There is no evidence that older patients require different dosages than younger adult patients. Taking into account age-related changes, such as decreased renal function and changes in hematological parameters, special caution is recommended when administering the drug in this age group.

children crowd

The safety and effectiveness of this product in children under 12 years of age have not been established. No data yet.

Suimeikai medication for pregnant and lactating women:

pregnancy

In general, animal data as well as clinical experience in pregnant women should be considered when deciding to use antiretroviral drugs to treat HIV infection in pregnant women to reduce the risk of vertical transmission of HIV to the newborn.

There are no data on the use of Trimax in pregnant women.

Data on the use of dolutegravir in pregnant women are limited or non-existent. The effects of dolutegravir on human pregnancy are unknown. Regarding the coadministration of abacavir and lamivudine in pregnant women, there is a limited amount of data indicating no teratogenic toxicity (more than 400 results from first-trimester exposure). Regarding lamivudine, extensive data (more than 3000 results from first-trimester exposure) indicate no teratogenic toxicity. Regarding abacavir, a certain amount of data (more than 600 results from first-trimester exposure) suggests no teratogenic toxicity.

In animal reproductive toxicity studies, dolutegravir was found to cross the placenta. Animal studies have not shown any direct or indirect harmful effects in terms of reproductive toxicity. Abacavir and lamivudine may inhibit cellular DNA replication, and abacavir has been shown to be carcinogenic in animal models. The clinical significance of these results is unclear.

Trimax should be used during pregnancy only if the expected benefits outweigh the risks to the fetus.

If a patient coinfected with hepatitis B virus is receiving lamivudine-containing medicines, such as Trimax, and subsequently becomes pregnant, the possibility of hepatitis recurrence should be considered when discontinuing lamivudine.

mitochondrial dysfunction

Nucleosides and nucleoside analogs have been shown to cause varying degrees of mitochondrial damage in vitro and in vivo. Mitochondrial dysfunction has been reported in HIV-negative infants exposed to nucleoside analogues in utero and/or postnatally.

breastfeeding

It is unclear whether dolutegravir is secreted into human milk. Existing animal toxicology data shows that dolutegravir can be secreted into milk. Lactating rats received 50 mg/kg dolutegravir orally on day 10 postpartum. The concentration of dolutegravir detected in milk is usually higher than that in blood.

Abacavir and its metabolites are excreted into the milk of lactating rats. Abacavir is also excreted in human milk.

Based on data from more than 200 mother/child pairs receiving HIV treatment, serum concentrations of lamivudine in infants breastfed by mothers receiving HIV treatment are extremely low (less than 4% of maternal serum concentrations) and tend to decrease gradually, reaching undetectable levels by the time the infant reaches 24 weeks of age. No safety data are available for infants younger than 3 months of age receiving abacavir and lamivudine.

It is recommended that HIV-infected women should not breastfeed their infants under any circumstances to avoid transmitting HIV.

fertility

There are no data on the effects of dolutegravir, abacavir, or lamivudine on male or female fertility. Animal studies have shown that dolutegravir, abacavir, or lamivudine has no effect on male or female fertility.

kidney damage

Patients whose creatinine clearance is less than 50 mL/min are not recommended to take this product.

liver damage

Abacavir is primarily metabolized by the liver. There are no clinical data in patients with moderate or severe hepatic impairment and therefore its use is not recommended unless considered necessary. For patients with mild hepatic impairment (Child-Pugh score 5-6), close monitoring is required, including monitoring of abacavir plasma levels if feasible.